Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma

Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,
https://plus.google.com/commun....ities/11546213005465
,
,https://plus.google.com/u/0/+A....lexandrosGSfakianaki
,
https://www.youtube.com/channe....l/UCQH21WX8Qn5YSTKrl
,
https://www.youtube.com/channe....l/UCTREJHxB6yt4Gaqs4
,
https://twitter.com/g_orl?lang=el,
https://www.instagram.com/alexandrossfakianakis/,


Merkel Cell Carcinoma
via Head and Neck Pathology
Abstract
Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma. Incidence of MCC continues to rise, and risk factors include advanced age, pale skin, chronic sun exposure, and immune suppression. Diagnosing MCC utilizes a combination of morphology and immunohistochemistry. Merkel cell polyomavirus (MCPyV) is present in approximately 70–80% of MCCs and represents a key pathogenic driver in those MCCs. In contrast, MCPyV-negative MCCs arise through progressive accumulation of ultraviolet-light induced somatic mutations. Staging of MCC proceeds according to the American Joint Commission on Cancer (AJCC) 8th Edition, which utilizes features of the primary tumor together with regional lymph node(s) (clinically and/or pathologically detected) and/or distant metastases. Many potentially useful biomarkers have been studied to refine risk stratification in MCC. In recent years, the host immune infiltrate has been leveraged as immune checkpoint blockade has emerged as an efficacious mode of treatment for patients with advanced MCC.